Xilio Therapeutics, Inc. (XLO)
8.10
-0.05
(-0.61%)
USD |
NASDAQ |
May 19, 16:00
8.10
0.00 (0.00%)
After-Hours: 20:00
Xilio Therapeutics Research and Development Expense (Quarterly) : 19.83M for March 31, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Verastem, Inc. | 38.22M |
| Opus Genetics, Inc. | 10.58M |
| Sensei Biotherapeutics, Inc. | 2.536M |
| ACADIA Pharmaceuticals, Inc. | 76.87M |
| Alnylam Pharmaceuticals, Inc. | 364.87M |